共 61 条
[33]
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)
[J].
CLINICAL MICROBIOLOGY AND INFECTION,
2018, 24
:S71-S82
[34]
FDA: Increased HBV Reactivation Risk With Ofatumumab or Rituximab
[J].
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,
2013, 310 (16)
:1664-1664
[35]
MOLICA S, 1993, HAEMATOLOGICA, V78, P374
[36]
Morrison V.A., 2022, Prevention of infections in patients with chronic lymphocytic leukemia
[37]
Morrison VA, 1998, SEMIN ONCOL, V25, P98
[39]
Nucci M, 2023, Infections in patients with multiple myeloma
[40]
Nucci M, 2013, Neoplastic diseases of the blood, P1149